Nuwellis, Inc.

Nuwellis, Inc. has officially announced a 1-for-9 reverse stock split, which was approved by its Board of Directors on October 13, 2026. The company filed a Certificate of Amendment to its Certificate of Incorporation on October 22, 2026, to effect this change. The reverse stock split will become effective after market close on October 26, 2026, with trading on a split-adjusted basis beginning on October 27, 2026. Any fractional shares resulting from the split will be rounded down, and stockholders will receive cash for these fractional amounts. The company's common stock will continue to be traded on the Nasdaq Capital Market under the symbol NUWE.

Nuwellis, Inc. reported strong financial results for the second quarter of 2026, with net sales increasing 14% year-over-year to $2.0 million and gross margin significantly improving to 76%. The company also reduced its net loss to $4.8 million from $12.6 million in the prior-year quarter. Strategic highlights include progress on Aquadex label expansion, the appointment of a new CEO, and successful capital raises totaling $12.7 million, extending its cash runway through Q2 2027.

Nuwellis, Inc. reported a narrowed net loss of $4.8 million for Q2 2026, down from $12.6 million in Q2 2025, with net sales increasing to $1.97 million. Despite improved financial performance, the company disclosed substantial doubt about its ability to continue as a going concern due to accumulated deficits and continued operating losses. Nuwellis raised $4.9 million in net proceeds from a June 2026 stock offering and $4.4 million from a January 2026 private placement to support operations.

Nuwellis, Inc. announced a digital transformation program for its Aquadex SmartFlow® System, aiming to position it as a connected extracorporeal therapy platform. The program includes integration with Philips Capsule™ technology and a new tablet-based user interface, designed to improve clinical workflow, enhance interoperability with hospital systems, and create a digital foundation for future software innovations. These research-stage initiatives are part of Nuwellis' broader strategy to expand the Aquadex platform's capabilities and clinical applications.

Nuwellis, Inc. announced the appointment of Dale Brady as Principal R&D Engineer. Brady brings over 25 years of medical device leadership experience in research and development, operations, manufacturing, quality systems, and commercialization. He will join Nuwellis' R&D team to advance existing and new product development programs, leveraging his expertise in bringing innovative products from concept through commercial launch. The company's CEO and VP of R&D highlighted his technical depth and ability to accelerate innovation.

Nuwellis, Inc. announced strategic development initiatives to expand the capabilities of its Aquadex SmartFlow® System. The program aims to evolve the system into a broader extracorporeal therapy platform by enhancing operating parameters to support higher blood flow rates, expanded pressure ranges, and broader compatibility with advanced therapies. This initiative is intended to expand the company's addressable market beyond fluid overload into critical care applications such as blood purification, immunomodulation, and extracorporeal life support, also enabling future strategic collaborations. These expanded applications are currently research-stage and not yet FDA approved or commercially available.

Nuwellis, Inc. announced the pricing and closing of a registered direct offering and concurrent private placement, generating approximately $3.4 million in gross proceeds. The company sold 1,310,890 shares of common stock at $2.59 per share and issued warrants to purchase an equal number of shares at the same exercise price. Additionally, Nuwellis received $3.1 million from the exercise of previously issued warrants from a June 2026 public offering.

Nuwellis, Inc. announced the acceptance of a new single-center retrospective study in Frontiers in Pediatrics. The study demonstrates that epoprostenol can serve as a safe and feasible alternative anticoagulant during Aquadex therapy in critically ill pediatric patients. This research provides important real-world data supporting an alternative anticoagulation strategy for patients who may not be candidates for conventional therapies, further strengthening the clinical evidence for Aquadex therapy in pediatric critical care.

Nuwellis, Inc. announced strong preliminary unaudited results for the second quarter and first half of 2026, with revenue growing 14% year-over-year for Q2 and 20% for the first six months. This growth is attributed to the continued commercial momentum of its Aquadex Ultrafiltration platform. The company plans to release its full financial results for the period on August 13, 2026, followed by a conference call and webcast.

Nuwellis, Inc. announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,678,592 for its Dual Lumen Catheter. This novel peripheral catheter is designed for extracorporeal therapies like ultrafiltration and dialysis, featuring a reinforcing stainless-steel coil to prevent collapse and allowing for customizable length. The patent strengthens Nuwellis' intellectual property and aims to address clinical challenges by improving therapy performance and flexibility for patients.